Improvement of ۵-fluorouracil chemosensitivity in colorectal cancer cells by siRNA-mediated silencing of STAT۶ oncogene

Publish Year: 1403
نوع سند: مقاله ژورنالی
زبان: English
View: 77

This Paper With 10 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-27-4_010

تاریخ نمایه سازی: 14 بهمن 1402

Abstract:

Objective(s): Colorectal cancer (CRC) remains a major health concern worldwide due to its high incidence, mortality rate, and resistance to conventional treatments. The discovery of new targets for cancer therapy is essential to improve the survival of CRC patients. Here, this study aims to present a finding that identifies the STAT۶ oncogene as a potent therapeutic target for CRC.Materials and Methods: HT-۲۹ CRC cells were transfected with STAT۶ siRNA and treated with ۵-fluorouracil (۵-FU) alone and combined. Then, to evaluate cellular proliferation and apoptosis percentage, MTT assay and annexin V/PI staining were carried out, respectively. Moreover, the migration ability of HT-۲۹ cells was followed using a wound-healing assay, and a colony formation assay was performed to explore cell stemness features. Gene expression was quantified via qRT-PCR. Afterward, functional enrichment analysis was used to learn in-depth about the STAT۶ co-expressed genes and the pathways to which they belong.Results: Our study shows that silencing STAT۶ with small interfering RNA (siRNA) enhances the chemosensitivity of CRC cells to ۵-FU, a commonly used chemotherapy drug, by inducing apoptosis, reducing proliferation, and inhibiting metastasis. These results suggest that combining ۵-FU with STAT۶-siRNA could provide a promising strategy for CRC treatment.Conclusion: Our study sheds light on the potential of STAT۶ as a druggable target for CRC cancers, the findings offer hope for more effective treatments for CRC patients, especially those with advanced stages that are resistant to conventional therapies.

Authors

Omid Rahbar Farzam

Department of Medical Biotechnology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

Behzad Baradaran

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Bahman Akbari

Department of Medical Biotechnology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

Soozan Najafi

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Mohammad Amini

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

AmirHossein Yari

Department of Biology, Tabriz Branch, Islamic Azad University, Tabriz, Iran

Reza Dabbaghipour

Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

Vahid Pourabdollah Kaleybar Pourabdollah Kaleybar

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Shiva Ahdi Khosroshahi

Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Xi Y, Xu P. Global colorectal cancer burden in ۲۰۲۰ ...
  • Siegel R, DeSantis C, Jemal A. Colorectal cancer statistics, ۲۰۱۴. ...
  • Sawicki T, Ruszkowska M, Danielewicz A, Niedźwiedzka E, Arłukowicz T, ...
  • Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: ...
  • Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, ...
  • Fatima I, Singh AB, Dhawan P. MASTL: A novel therapeutic ...
  • Nakamura K, Lila ASA, Matsunaga M, Doi Y, Ishida T, ...
  • Salguero-Aranda C, Sancho-Mensat D, Canals-Lorente B, Sultan S, Reginald A, ...
  • Salguero-Aranda C, Sancho-Mensat D, Sultan S, Reginald A, Chapman L. ...
  • Huang H, Zheng Y, Li L, Shi W, Zhang R, ...
  • Tang Z, Li C, Kang B, Gao G, Li C, ...
  • Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, ...
  • Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, ...
  • Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, ...
  • Wang S-W, Sun Y-M. The IL-۶/JAK/STAT۳ pathway: potential therapeutic strategies ...
  • Verhoeven Y, Tilborghs S, Jacobs J, De Waele J, Quatannens ...
  • Wei L, Wang X, Lv L, Zheng Y, Zhang N, ...
  • van Meir H, G Kenter G, Burggraaf J, R Kroep ...
  • Khosravi N, Shahgoli VK, Amini M, Safaei S, Mokhtarzadeh A, ...
  • Jiang L, Zhao X-H, Mao Y-L, Wang J-F, Zheng H-J, ...
  • Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, ...
  • Wang Y, Zhou BP. Epithelial-mesenchymal transition in breast cancer progression ...
  • Guo L, Cheng X, Chen H, Chen C, Xie S, ...
  • Guo F, Liu J, Han X, Zhang X, Lin T, ...
  • Barillari G. The impact of matrix metalloproteinase-۹ on the sequential ...
  • Mendoza-Rodríguez MG, Sánchez-Barrera CÁ, Callejas BE, García-Castillo V, Beristain-Terrazas DL, ...
  • Zhang S, Yang X, Wang L, Zhang C. Interplay between ...
  • Wahab SR, Islam F, Gopalan V, Lam AK-y. The identifications ...
  • Chanmee T, Ontong P, Kimata K, Itano N. Key roles ...
  • Agingu C, Zhang C-y, Jiang N-w, Cheng H, Özcan M, ...
  • Zheng J, Xu L, Pan Y, Yu S, Wang H, ...
  • Goenka S, Kaplan MH. Transcriptional regulation by STAT۶. Immunol Res ...
  • Park JG, Aziz N, Cho JY. MKK۷, the essential regulator ...
  • Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, ...
  • Ahuja N, Kumar P, Bhatnagar R. The adenylate cyclase toxins. ...
  • Moody TW, Nuche-Berenguer B, Jensen RT. Vasoactive intestinal peptide/pituitary adenylate ...
  • Cooper DM, Tabbasum VG. Adenylate cyclase-centred microdomains. Biochem J ۲۰۱۴; ...
  • Li W, Sang M, Hao X, Jia L, Wang Y, ...
  • نمایش کامل مراجع